The Netherlands-based diagnostics company, Qiagen NV, has reached an agreement with Pfizer Inc to develop a companion diagnostic for its immunotherapy vaccine, which is currently in Phase 2 development.
Privately-owed French pharmaceutical company, Pierre Fabre SA, has licensed exclusive rights to Abbott Laboratories to a preclinical monoclonal antibody for cancer that targets a membrane receptor known as c-Met.
As those who attend medical conferences know well, biotech executives like to talk about what they do in terms of models.
Galápagos NV, which performs discovery research for itself and for other companies using a functional genomics platform, has acquired Argenta Discovery Ltd, a privately-held contract research organization, for €16.5 million in cash.
A private equity group with offices in London and Guernsey is providing £5 million over three years to a UK company pursuing a new concept in biologic development.
Ipsen SA of France is combining its holdings of potential haemophilia drugs with those of Inspiration Biopharmaceuticals Inc of California, US to create a franchise that Ipsen hopes will exceed $1 billion by 2020.
The privately-held Danish diagnostics company, Dako Denmark A/S, has signed a deal with AstraZeneca to develop companion diagnostic tests for a number of AstraZeneca’s oncology projects. Financial details were not disclosed.
BioMedPartners of Switzerland said that it has closed its second healthcare venture capital fund, BioMedInvest II, at CHF 106 million (€71.7 million). The new fund will invest in private, early to mid-stage healthcare companies in Europe.
Bavarian Nordic A/S, the Danish vaccine developer, has fixed the terms for its DKK 318.1 million (€42.7 million) rights issue.
Galápagos NV has entered into an alliance with Roche to develop potential therapies for chronic obstructive pulmonary disease (COPD). Galápagos has received €6 million upfront and said potential milestone payments could exceed €400 million.